The Food & Drug Administration has approved Intelence's expanded use and makes it the only non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for this use in both treatment-experienced children and adults with resistance to an NNRTI and other antiretrovirals (ARVs). This is a drug developed by Janssen Products – a subsidiary of Johnson & Johnson.
